(18)F-DCFPyL Articles

To analyze variables that can predict the positivity of 18F-DCFPyL- positron emission tomography/computed tomography (PET/CT) and extent of disease in patients with biochemically recurrent (BCR) prostate cancer after primary local therapy with either radical prostatectomy or radiation therapy.

We present the case of a 79-year-old man with an elevated post-prostatectomy PSA level who was sequentially imaged with PET/CT using (18)F-fluciclovine followed by PSMA-targeted (18)F-DCFPyL. Although both imaging tests successfully identified the same pelvic recurrence, each radiotracer had its relative merits.

To prospectively evaluate the diagnostic performance of PSMA-targeted (18)F-DCFPyL PET/CT in the preoperative staging of men at high risk of harboring metastatic prostate cancer despite a negative conventional staging evaluation.

Men with biochemically relapsed prostate cancer face a clinical conundrum. Depending on the detected distribution of disease, treatment goals may range from cure with focal therapy to palliative with systemic therapy to expectant observation.